|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FRK |
Gene summary for FRK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FRK | Gene ID | 2444 |
| Gene name | fyn related Src family tyrosine kinase | |
| Gene Alias | GTK | |
| Cytomap | 6q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P42685 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2444 | FRK | RNA-P17T-P17T-6 | Human | Lung | IAC | 2.63e-07 | 7.91e-01 | 0.3385 |
| 2444 | FRK | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.05e-05 | 5.86e-01 | 0.3329 |
| 2444 | FRK | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 5.94e-07 | 4.59e-01 | -0.2116 |
| 2444 | FRK | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.41e-02 | 3.18e-01 | -0.2119 |
| 2444 | FRK | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.47e-07 | 3.65e-01 | -0.0166 |
| 2444 | FRK | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 9.80e-09 | 3.53e-01 | -0.0132 |
| 2444 | FRK | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.25e-10 | 3.58e-01 | -0.013 |
| 2444 | FRK | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.05e-06 | 3.59e-01 | -0.0121 |
| 2444 | FRK | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 4.47e-03 | 4.33e-01 | -0.0961 |
| 2444 | FRK | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 4.29e-04 | 5.63e-01 | -0.0876 |
| 2444 | FRK | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 6.87e-03 | 4.46e-01 | -0.0822 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:0018212 | Lung | AIS | peptidyl-tyrosine modification | 56/1849 | 378/18723 | 1.35e-03 | 1.68e-02 | 56 |
| GO:0018108 | Lung | AIS | peptidyl-tyrosine phosphorylation | 55/1849 | 375/18723 | 1.87e-03 | 2.08e-02 | 55 |
| GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FRK | SNV | Missense_Mutation | c.191N>C | p.Arg64Pro | p.R64P | P42685 | protein_coding | deleterious(0.02) | benign(0.406) | TCGA-E2-A1IG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| FRK | SNV | Missense_Mutation | c.1443N>T | p.Glu481Asp | p.E481D | P42685 | protein_coding | tolerated(0.16) | possibly_damaging(0.85) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FRK | SNV | Missense_Mutation | c.1348N>C | p.Tyr450His | p.Y450H | P42685 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| FRK | SNV | Missense_Mutation | novel | c.807N>T | p.Met269Ile | p.M269I | P42685 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FRK | SNV | Missense_Mutation | c.536N>A | p.Arg179Gln | p.R179Q | P42685 | protein_coding | tolerated(0.39) | benign(0.019) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FRK | SNV | Missense_Mutation | c.11T>C | p.Ile4Thr | p.I4T | P42685 | protein_coding | tolerated_low_confidence(0.09) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FRK | SNV | Missense_Mutation | novel | c.1364C>T | p.Pro455Leu | p.P455L | P42685 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FRK | SNV | Missense_Mutation | novel | c.1363C>G | p.Pro455Ala | p.P455A | P42685 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FRK | SNV | Missense_Mutation | c.381N>T | p.Glu127Asp | p.E127D | P42685 | protein_coding | deleterious(0.03) | possibly_damaging(0.567) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| FRK | SNV | Missense_Mutation | c.824N>C | p.Leu275Pro | p.L275P | P42685 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | TAMATINIB | R-406 | ||
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | NINTEDANIB | NINTEDANIB | |
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | RG-1530 | RG-1530 | ||
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | GEFITINIB | GEFITINIB | ||
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | ALISERTIB | ALISERTIB | ||
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL1421 | DASATINIB | |
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL1980297 | ILORASERTIB | |
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | IMATINIB | IMATINIB | ||
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL3545085 | XL-228 | |
| 2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | ILORASERTIB | ILORASERTIB |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |